ArticleThe Laryngoscope2025
Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phonosurgical Treatment of Laryngeal Leukoplakia and Dysplasia: Results of Multidimensional Voice Diagnostics Including the VEM.Diagnostics (Basel, Switzerland) · 2026Article
- Moderate Laryngeal Dysplasia in the Context of Classification Systems and Clinical Decision Making.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesDetermining the prognosis of vocal fold leukoplakia remains challenging. The 2017 WHO Classification of Head and Neck Tumors proposed a two-tier grading system for classifying laryngeal precursor lesions. This resulted in the upstaging of "moderate dysplasia" to "high-grade dysplasia." The aim of this study was to retrospectively analyze the rates of malignant transformation in relation to the grade of dysplasia.
methodsTotally, 392 patients who underwent at least one microlaryngoscopy with biopsy for laryngeal leukoplakia were included in this study. The rate and time to malignant transformation were analyzed according to the histopathological diagnosis and the localization of the leukoplakia.
resultsMalignant transformation rates (defined as de novo occurrence of an invasive carcinoma) were low for hyperkeratosis or parakeratosis and mild dysplasia, but comparably high for moderate dysplasia, severe dysplasia, and carcinoma in situ (CIS) (6% vs. 9% vs. 41% vs. 43% vs. 55%). The time between first biopsy and malignant transformation varied widely (0.1-10.8 years) and did not show a significant dependence on the initial histopathological diagnosis.
conclusionBased on the observed malignant transformation rates, the data support classifying moderate dysplasia into the "high-grade" dysplasia group, in line with the fourth WHO classification from 2017. This implies that the clinical management of moderate dysplasia should align with that of severe dysplasia and CIS, involving histologically controlled resection. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.